July 24, 2006 -- Shire won approval of Elaprase for a rare genetic disorder called Hunter syndrome; Bayer and Onyx received European approval for Nexavar, a treatment for kidney cancer; AstraZeneca got an FDA OK for asthma treatment Symbicort; Nektar received a $17.6 million payment from Affymax for an anemia drug; ViaCell completed treatment on patients in a Phase I trial of its umbilical cord stem cell therapy; the stock of Prana benefited from a news report about its Alzheimer’s drug; Merck reported earnings of $1.5 billion on worldwide revenue of $5.8 billion, an increase of 6%; and Biovail ended its collaboration with Athpharma. The Centient Biotech 200™ rose 72 points to 3589.14, an increase of 2.04%. More details...
